Article

Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

You might want to recommend this clinical trial to your patients with metastatic melanoma which evaluates whether preparatory chemotherapy followed by infusion of DMF5 cells is a safe and effective for shrinking melanoma tumors.

Study Type: InterventionalAge/Sex Requirement: 18 years+ (None)

Sponsor: National Cancer Institute

ClinicalTrials.gov Identifier: NCT00924001

Purpose: To determine whether preparatory chemotherapy followed by infusion of DMF5 cells is a safe and effective for shrinking melanoma tumors. The primary outcomes measure is clinical response according to RECIST criteria and toxicity. The secondary outcomes measure is the rate of repopulation of young TIL cells as well as correlates that predict in vivo persistence and clinical response.

Click here to learn more about this clinical trial.

Related Videos
Abdul Abdellatif, MD: More Gout Education Needed for Nephrologists
Violeta Popov, MD, PhD | Credit: ACG
Satish Rao, MD, PhD | Credit: ACG
Jonathan Barratt, MD, PhD | Credit: IgA Nephropathy Foundation
Jonathan Barratt, MD, PhD | Credit: IgA Nephropathy Foundation
Jonathan Barratt, MD, PhD | Credit: IgA Nephropathy Foundation
Jonathan Barratt, MD, PhD | Credit: IgA Nephropathy Foundation
Jonathan Barratt, MD, PhD | Credit: IgA Nephropathy Foundation
Ladan Zand, MD: Evaluating Obinutuzumab in Primary FSGS and Further Research
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
© 2024 MJH Life Sciences

All rights reserved.